Latest stories on REGN
Alvotech seeks U.S. nod for biosimilars to J&J’s Simponi and Regeneron’s Eylea again
Seeking Alpha67 · bullishproduct/pr
Regeneron backed Parabilis seeks up to $476M in U.S. IPO
Seeking Alpha58 · neutralanalyst
CytomX Expands High-Value Bispecific Cancer Partnership With Regeneron
TipRanks67 · bullishproduct/pr
CytomX gains as licensing deal with Regeneron expands
Seeking Alpha67 · bullishproduct/pr
uniQure: Why A Shifting FDA Could Change Everything For AMT-130
Seeking Alpha58 · neutralanalyst
Is Regeneron Pharmaceuticals Stock Underperforming the Dow?
Barchart53 · neutralgeneral
Is Regeneron Pharmaceuticals Stock Underperforming the Dow?
Yahoo Top47 · neutralgeneral
Regeneron (REGN) Says EMA Accepted Review for Otarmeni Application
Yahoo Top58 · neutralproduct/pr
Regeneron Steps Into CAR T for Advanced Prostate Cancer With New Phase 1 Trial
TipRanks58 · neutralproduct/pr
Regeneron, Gilead therapies eyed as potential Ebola treatments by WHO
Seeking Alpha58 · neutralproduct/pr
Canaccord Cuts PT on Regeneron Pharmaceuticals (REGN), Cites a Disappointing Event
Yahoo Top33 · bearishanalyst
Are Wall Street Analysts Predicting Regeneron Pharmaceuticals Stock Will Climb or Sink?
Barchart58 · neutralanalyst
Are Wall Street Analysts Predicting Regeneron Pharmaceuticals Stock Will Climb or Sink?
Yahoo Top58 · neutralanalyst
Regeneron (REGN) Enters $2.32B Collaboration With Parabilis to Target ‘Undruggable’ Proteins
Yahoo Top67 · bullishproduct/pr
Parabilis Medicines Starts IPO On Promising Cancer Therapy Trials
Seeking Alpha67 · bullishproduct/pr
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss | REGN Stock News
StockTitan67 · bullishproduct/pr
Jim Cramer on Regeneron: “There Could Be Some More Downgrades”
Yahoo Finance33 · bearishanalyst
Regeneron backed Parabilis Medicines seeks U.S. IPO
Seeking Alpha58 · neutralgeneral
REGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law Violations
PR Newswire33 · bearishgeneral
Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck’s Keytruda
Yahoo Top22 · bearishproduct/pr